Human Papillomavirus 16 E2 as an Apoptosis-Inducing Protein for Cancer Treatment: A Systematic Review

Int J Mol Sci. 2022 Oct 19;23(20):12554. doi: 10.3390/ijms232012554.

Abstract

Human papillomavirus type 16 (HPV-16) is a well-known etiological factor for cervical and oropharyngeal cancers. The E2 protein, the product of an early-transcribed gene in HPV-16, is postulated to cause the death of cancerous cells via p53-dependent and p53-independent pathways. The main aim of the present systematic review was to study the HPV 16-E2 protein as an apoptosis-inducer agent. A thorough search of MEDLINE/PubMed, Science Direct, Scopus, and EBSCOhost databases was conducted for relevant studies on HPV AND apoptosis OR cell death where HPV 16-E2 was involved. The search identified 967 publications. Eleven records dated from 1 January 1997 to 16 February 2022 were found to meet the inclusion criteria and were eligible for data extraction and inclusion. All studies concluded that HPV 16-E2 was able to induce cell death in transfected cells. E2 proteins from the high-risk HPV-16 were able to induce apoptosis through different apoptotic pathways depending on the location of the expressed gene. However, the mechanism was still unclear, and further studies are warranted.

Keywords: E2 protein; HPV 16; apoptosis; cell death; human papillomavirus.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Apoptosis / genetics
  • Apoptosis Regulatory Proteins / metabolism
  • Female
  • Human papillomavirus 16 / metabolism
  • Humans
  • Oncogene Proteins, Viral* / genetics
  • Oropharyngeal Neoplasms*
  • Papillomaviridae / genetics
  • Papillomavirus Infections*
  • Tumor Suppressor Protein p53 / metabolism
  • Uterine Cervical Neoplasms* / genetics

Substances

  • Apoptosis Regulatory Proteins
  • Tumor Suppressor Protein p53
  • Oncogene Proteins, Viral